Irvine Pharmaceutical Services Announces the Opening of an Analytical Facility in Hangzhou, China

DATE OF RELEASE October 30, 2014 IRVINE, CA - Irvine Pharmaceutical Services, Inc., a leading provider in cGMP contract development and parenteral manufacturing services, announces plans to open a new facility in Hangzhou, China. This 115,000sqft. newly built, state-of-the-art facility will expand Irvine's service offerings into the Asian markets. Irvine's newest facility is scheduled to be fully operational in the first quarter of 2015. CEO and Founder, Dr. Assad J. Kazeminy explains, "Irvine is responding to the rising needs of large multi-national pharmaceutical companies that are looking for contract organizations overseas that include robust cGMP quality infrastructure and technical expertise. Irvine will now have a local presence and a strong understanding of the local market to offer the region high quality analytical support." Learn more about Irvine's expansion into the Asian market – Visit us at booth 3110 at the 2014 AAPS Annual Meeting and Exposition in San Diego, CA on November 2 – 6, 2014. About Irvine Irvine Pharmaceutical Service Inc. is a premier contract development and manufacturing organization providing support to the pharmaceutical, biopharmaceutical, and medical device industries. Irvine provides cGMP contract development and manufacturing services such as parenteral manufacturing (liquid and lyophilized), preformulation/formulation development, analytical development, biopharmaceutical development, stability storage, analytical chemistry, structural chemistry, microbiology, and drug delivery device testing. Learn more at www.irvinepharma.com or call (949) 951-4425. Irvine Pharmaceutical Services, Inc. 10 Vanderbilt Irvine, California 92618 T: (877) 445-6554 F: (949) 951-4909 www.irvinepharma.com

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.